J. Ford

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

Brian Druker, Moshe Talpaz, Debra Resta et al. · New England Journal of Medicine · 2001 · 5.2K citations · Full text

Medicine, Oncology, Pharmacology +12

Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

Brian Druker, Charles L. Sawyers, Hagop M. Kantarjian et al. · New England Journal of Medicine · 2001 · 2.7K citations · Full text

Medicine, Hematology, Oncology +17

Pharmacokinetics and Pharmacodynamics of Imatinib in a Phase I Trial With Chronic Myeloid Leukemia Patients

Bin Peng, Michael Hayes, Debra Resta et al. · Journal of Clinical Oncology · 2004 · 470 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +13

Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.

Antonio Piga, Renzo Galanello, Maria Domenica Cappellini et al. · PubMed · 2006 · 269 citations · Full text

Medicine, Hematology, Pharmacology +17

Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.

PierFranco Conte, Jean Latreille, L. Mauriac et al. · Journal of Clinical Oncology · 1996 · 268 citations

Medicine, Orthopedic Surgery, Pharmacology +17